Cardioprotective effect of quercetin supplement in against of cardiac induced toxicity of doxorubicin in breast cancer patients: a randomized, double-blined, placebo-controlled trial.

Rasht University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新: 2019年3月25日

适应症

试验速览

暂无简介。

•Eligible patients include women aged 21-69 years with sinus rhythm and normal ventricular drainage fraction, normal liver and kidney function, and normal hematology.Previously don`t have any document for chemotherapy or radiotherapy for other types of malignancies. They don`t have CHF. Have not experienced myocardial infarction. Do not suffer from obstruction or heart valves stenosis. They don`t have specific disease or specific drug therapy that affects cardiac function. EF do not have less than 55%.They don`t have cardiovascular disease risk factors , such as hypertension, high fat, and do not include smokers. Women in this clinical trial study are not pregnant and don`t have systolic pressure of less than 90 mmHg.

•Unwillingness to appear in the plan, to make any changes to the treatment or use of the drug. At any time from the implementation of the plan, in the event of any unwanted side effects, the oral supplement will be discontinued and the patient will be excluded from the study.

发起方

Rasht University of Medical Sciences